comparison of glp 1 receptor agonists PDB-101: Molecule the Month: GLP-1 Comparing Ozempic, Wegovy and Other
Description
Why the hype: Diabetes, obesity, and vascular disease are known contributors to brain aging and dementia risk
The segment also benefits from expanded FDA approval pathways, with 90% of new biosimilar applications receiving priority review in 2025
Medical Claims A key point of confusion arises from the "GLP-1" label
Yes, the FDA has approved generic versions of liraglutide (Victoza) and exenatide (Byetta)
The second important incretin hormone is GLP-1, released from L-cells in the distal ileum and colon (Gautier et al., 2008)
Coverage is highly plan-specific
